Interactions on record — worth a quick check against your medications. Based on 1 of 3 ingredients. Check your meds →
Dietary supplement

NTFactor EnergyLipids Ingredients & Drug Interactions

by Allergy Research Group

NTFactor EnergyLipids label
See full label image
Powder Category: Fat/fatty Acid
Most serious interaction: Moderate
Clinical methodology reviewed by · Updated Sep 16, 2026 · Label data from the NIH DSLD
What is this page for?

First and foremost: checking NTFactor EnergyLipids against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.

Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy

The interaction bottom line Most serious interaction: Moderate

NTFactor EnergyLipids is a dietary supplement by Allergy Research Group with 3 active ingredients. Its ingredients are commonly taken for bone health and osteoporosis, correcting vitamin d deficiency, immune system support.Based on those ingredients, 715 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Vitamin D3. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Jump to a section

Check Your Meds Against NTFactor EnergyLipids by Allergy Research Group

Ask about any prescription or over-the-counter medication and we check it for interactions with NTFactor EnergyLipids by Allergy Research Group — and tell you which ingredient is responsible.

Pharmacist-reviewed data Checks every ingredient Answer in seconds
Prefer a human? Send your question to our licensed pharmacists — free, answered by email within 24 hours.

HelloPharmacist Scorecard of NTFactor EnergyLipids by Allergy Research Group

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Last generated Aug 27, 2026

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 2 of its 2 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

NTFactor EnergyLipids contains 2 active ingredients: vitamin D3 and a proprietary blend called NTFactor Proprietary Blend. Vitamin D3 is a form of vitamin D, a fat-soluble nutrient that plays a key role in calcium absorption, bone health, and immune function.

The product also includes several inactive ingredients — fructooligosaccharides (a type of fiber), pantethine (a form of pantothenic acid), sodium borate, and rosemary extract — which serve as fillers, binders, or preservatives.

Does it work?

Not established
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not established

The graded evidence we hold for these ingredients covers different conditions than the ones this product is marketed for, so there's no established rating for its stated use — see Vitamin D's own graded uses on its monograph.

Why this rating?
  • The label markets this product for: Maintain vital energy.
  • We looked for evidence on: Fatigue, Cellular energy metabolism, Mitochondrial function, ATP production.
  • The closest evidence on file: Vitamin D is rated "Insufficient Reliable Evidence To Rate" for Post-stroke fatigue (Natural Medicines).

Vitamin D3 is effective for treating familial hypophosphatemia (low blood phosphate due to genetics), osteomalacia (soft bones from vitamin D deficiency), renal osteodystrophy (bone disease linked to kidney disease), rickets (childhood bone disease), and hypoparathyroidism (low parathyroid hormone). We hold no effectiveness data in our records for the NTFactor Proprietary Blend ingredient.

The evidence, ingredient by ingredient Vitamin D

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 1 of the 1 matched ingredient.
  • Pregnancy & breastfeeding safety ratings cover 1 of 1.
  • General safety write-ups exist for 1 of 1.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Vitamin D3 is generally well tolerated at recommended doses. However, very high doses taken over time can cause vitamin D toxicity, with symptoms including high calcium levels (hypercalcemia), bone loss, and — in children — slowed growth.

Serious side effects like calcific conjunctivitis (calcium deposits in the eye) and light sensitivity are rare. Vitamin D3 is likely safe during pregnancy at recommended doses, though the data also flags a possibly unsafe rating — use it only under your doctor's guidance during pregnancy.

It is likely safe during breastfeeding at recommended amounts, but check with your doctor before taking higher doses.

Side effects, ingredient by ingredient Vitamin D

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 1 matched ingredient can interact with medications — Vitamin D.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: heart-rhythm medications.
  • For scale: 716 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking NTFactor EnergyLipids, check with your doctor or pharmacist if you take any of these medication types: heart rhythm drugs (digoxin, verapamil, diltiazem), thiazide diuretics, atorvastatin, calcipotriene (topical psoriasis treatment), aluminum-containing products, or any medications broken down by the liver enzyme CYP3A4. High-dose vitamin D3 in this product can raise calcium levels or reduce how well some of these drugs work.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with no established evidence rating for its marketed use. Moderate medication interactions have been identified, and safety information is well characterized.

NTFactor EnergyLipids is designed for people who need vitamin D3 supplementation for bone or mineral disorders. If you take heart rhythm medications (digoxin, verapamil, diltiazem), a thiazide diuretic, atorvastatin, or any aluminum-containing product, check your exact medications with your doctor or pharmacist before starting this product — the vitamin D3 content can interfere with how these drugs work or raise your calcium to unsafe levels.

Also avoid very high doses to prevent toxicity.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 1 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jan 24, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about NTFactor EnergyLipids, straight from the product label.

Brand Allergy Research Group
Barcode (UPC) 713947767102
Net contents 150 Gram(s); 5.3 Ounce(s)
Market status On market
Date entered into DSLD Jan 24, 2024
DSLD ID 304264
Product type Fat/fatty Acid
Supplement form Powder
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for NTFactor EnergyLipids by Allergy Research Group, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Scoop(s)
Maximum serving Sizes:
2 Scoop(s)
Servings per container
120
UPC/BARCODE
713947767102
IngredientAmount% DV
Calories10 Calorie(s)--
Total Carbohydrates456 mg1%
Calories from Fat5 Calorie(s)--
Total Sugars36 mg--
Total Fat551 mg1%
Protein80 mg1%
Vitamin D30.7 mcg7%
NTFactor Proprietary Blend1.087 Gram(s)--

Other ingredients: Fructooligosaccharides, Pantethine, Sodium Borate, Rosemary Extract

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Patented NTFactor phosphoglycolipids from soy, in proprietary and scientifically selected ratios of phosphatidylcholine, glycolipids, and other phosphatidyl nutrients, researched and blended to optimize cellular uptake and membrane utilization.

Suggested/Recommended/Usage/Directions

Suggested use As a dietary supplement, 1 scoop two times daily, or as directed by a healthcare practitioner. A larger dose of 2 scoops two times daily may be taken during an initial one to two month loading period. May be mixed with water, juice, or food. Sensitive individuals may want to start with less. Use within 30-60 days of opening.

Storage

Use within 30-60 days of opening. Store tightly sealed at room temperature, away from direct sunlight.

General Statements

Product is sold by weight, not volume.

FDA Disclaimer Statement

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Formulation

Maintain vital energy

FDA Statement of Identity

Dietary Supplement

Brand IP Statement(s)

NTFactor (Patent 8,877,239)

Is this label outdated? Report a formula or label change and our pharmacy team will review it.

See for yourself

NTFactor EnergyLipids by Allergy Research Group label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

NTFactor EnergyLipids label

Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.

View the full label (PDF)
What’s inside

The Ingredients in NTFactor EnergyLipids by Allergy Research Group

These are the 3 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Scoop(s) Dosage formPowder Servings per container120 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Protein

80 mg per serving

Vitamin D3

Interacts with
715 drugs
0.7 mcg per serving

Vitamin D is a fat-soluble vitamin that helps your body absorb calcium and is important for healthy bones, muscles, and immune function. Many people,...

Vitamin D3 monograph & interactions

NTFactor Proprietary Blend

1.087 Gram(s) per serving Form: Soy Lecithin extract

Other (inactive) ingredients: Fructooligosaccharides, Pantethine, Sodium Borate, Rosemary Extract. These complete the product’s ingredient list but are not active constituents.

Interaction report

NTFactor EnergyLipids by Allergy Research Group Drug Interactions

Want to check YOUR meds against NTFactor EnergyLipids?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

 Go to the checker
715Drugs
80 Moderate 635 Minor

Ingredients driving the most interactions

Vitamin D3 715

Individual Drug Interactions

The ingredients in NTFactor EnergyLipids interact with 715 drugs. Click any drug to see the details.

1 of the 3 ingredients in NTFactor EnergyLipids interact with drugs. Each result below shows which ingredient is responsible. Vitamin D3

Each ingredient & the kinds of drugs it affects

For each ingredient in NTFactor EnergyLipids with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

Vitamin D38 drug types · 715 drugs

Aluminum

Vitamin D might increase aluminum absorption and toxicity, but this has only been reported in people with renal failure.
The protein that transports calcium across the intestinal wall can also bind and transport aluminum. This protein is stimulated by vitamin D, which may therefore increase aluminum absorption. This mechanism may contribute to increased aluminum levels and toxicity in people with renal failure, when they take vitamin D and aluminum-containing phosphate binders chronically.

Likelihood Probable Evidence B
Atorvastatin (Lipitor)

Vitamin D might reduce absorption of atorvastatin.
A small, low-quality clinical study shows that taking vitamin D reduces levels of atorvastatin and its active metabolites by up to 55%. However, while atorvastatin levels decreased, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels did not substantially change. Atorvastatin is metabolized in the gut by CYP3A4 enzymes, and researchers theorized that vitamin D might induce CYP3A4, causing reduced levels of atorvastatin. However, this proposed mechanism was not specifically studied.

Likelihood Probable Evidence B
Calcipotriene (Dovonex)

Taking calcipotriene with vitamin D increases the risk for hypercalcemia.
Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia. Theoretically, combining calcipotriene with vitamin D supplements might increase the risk of hypercalcemia.

Likelihood Probable Evidence D
Digoxin (Lanoxin)

Theoretically, hypercalcemia induced by high-dose vitamin D can increase the risk of arrhythmia from digoxin.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and digoxin concurrently.

Likelihood Possible Evidence D
Diltiazem (Cardizem, Others)

Theoretically, hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of diltiazem for arrhythmia.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically this could also occur with diltiazem. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and diltiazem concurrently.

Likelihood Probable Evidence B
Thiazide Diuretics

Theoretically, taking thiazide diuretics and high-dose vitamin D can increase the risk of hypercalcemia.
Thiazide diuretics decrease urinary calcium excretion, which could lead to hypercalcemia if vitamin D supplements are taken concurrently. This has been reported in people being treated with vitamin D for hypoparathyroidism, and also in elderly people with normal parathyroid function who were taking a thiazide, vitamin D, and calcium-containing antacids daily.

Likelihood Probable Evidence D
Verapamil (Calan, Others)

Hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of verapamil for arrhythmia.
Hypercalcemia due to high doses of vitamin D can reduce the effectiveness of verapamil in atrial fibrillation. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and verapamil concurrently.

Likelihood Probable Evidence B
Cytochrome P450 3A4 (Cyp3A4) Substrates

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
There is some concern that vitamin D might induce CYP3A4. In vitro research suggests that vitamin D induces CYP3A4 transcription. Additionally, observational research has found that increased UV light exposure and serum vitamin D levels are associated with decreased serum levels of CYP3A4 substrates such as tacrolimus and sirolimus, while no association between UV light exposure or vitamin D levels and levels of mycophenolic acid, a non-CYP3A4 substrate, was found. A small, low-quality clinical study shows that taking vitamin D reduces levels of the CYP3A4 substrate atorvastatin and its active metabolites by up to 55%; however, the clinical effects of atorvastatin were not reduced. While researchers theorized that vitamin D might induce CYP3A4, this proposed mechanism was not specifically studied.

Likelihood Possible Evidence D
Vitamin D3 full monograph & interactions
The maker

Brand information

Manufacturer and brand details for NTFactor EnergyLipids, from the product label.

Allergy Research Group

See all Allergy Research Group products
Name
Allergy Research Group
City
South Salt Lake
State
UT
ZipCode
84115
Phone Number
800-545-9960
Web Address
www.allergyresearchgroup.com
Pharmacist Counseling Corner

NTFactor EnergyLipids by Allergy Research Group: Common Questions

Does NTFactor EnergyLipids by Allergy Research Group interact with any medications?
Yes. Based on its ingredients, NTFactor EnergyLipids has a known interaction with 715 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
NTFactor EnergyLipids contains 3 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is NTFactor EnergyLipids safe to take if I'm pregnant?
Vitamin D3 is rated likely safe at recommended doses during pregnancy, but the data also includes a possibly unsafe rating. You should take it only under your doctor's guidance during pregnancy so they can personalize the recommendation for you.
Can I take this if I'm breastfeeding?
Vitamin D3 is likely safe during breastfeeding at recommended doses. Check with your doctor before taking higher amounts.
What does vitamin D3 actually do in this product?
Vitamin D3 helps your body absorb calcium and is used to treat bone and mineral disorders like rickets, osteomalacia, and hypoparathyroidism. It's also important for immune function and overall health.
What happens if I take too much of this product?
Very high doses of vitamin D3 over time can cause vitamin D toxicity. Symptoms include high calcium levels (hypercalcemia), bone loss, and in children, slowed growth. In rare cases, you may develop calcium deposits in the eyes or light sensitivity.
Does this product have any fillers?
Yes — it contains inactive ingredients including fructooligosaccharides, pantethine, sodium borate, and rosemary extract, which serve as fillers, binders, and preservatives.
Can I check if my medications interact with this before I buy it?
Yes — use the medication checker on this page to search your exact drugs. Vitamin D3 interacts with a number of medications, including heart rhythm drugs, blood pressure pills, and cholesterol medications, so it's worth checking first.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if NTFactor EnergyLipids is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

NTFactor EnergyLipids label
Go deeper

The Full Monographs Behind NTFactor EnergyLipids’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Vitamin D

Interacts with 715 drugs

Vitamin D is a fat-soluble vitamin that helps your body absorb calcium and is important for healthy bones, muscles, and immune function. Many people, especially those with low sun exposure,...

Read the full Vitamin D monograph →
Sources

Sources & How We Checked

NTFactor EnergyLipids's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 26 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Vitamin D 26 references
  1. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  2. Tatro DS, ed. Drug Interactions Facts. Facts and Comparisons Inc., St. Louis, MO. 1999.
  3. Koutkia P, Chen TC, Holick MF. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 2001;345:66-7. PubMed
  4. Bar-Or D, Yoel G. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6.
  5. Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking AI(OH)3. Clin Nephrol 1986;26:146-9.
  6. Crowe M, Wollner L, Griffiths RA. Hypercalcemia following vitamin D and thiazide therapy in the elderly. Practitioner 1984;228:312-3.
  7. Parfitt AM. Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism. Ann Intern Med 1972;77:557-63. PubMed
  8. Thiazide diuretics and the risk of osteoporosis. Pharmacist's Letter/Prescriber's Letter 2003;19(11):191105.
  9. Moon J. The role of vitamin D in toxic metal absorption. J Am Coll Nutr 1994;13:559-64.
  10. Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1alphaOH vitamin D<SUB>3</SUB> increases the intestinal absorption of aluminum. Clin Nephrol 1989;31:123-7.
  11. Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol 1985;249:G209-13. PubMed
  12. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: A new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203. PubMed
  13. Dietary reference intakes for calcium and vitamin D. Institute of Medicine, November 30, 2010. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Repo
  14. Cox KA, Dunn MA. Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. J Nutr 2001;131:2007-13. PubMed
  15. Escribano, J., Balaguer, A., Pagone, F., Feliu, A., and Roque, I. Figuls. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane.Database.Syst.Rev. 2009;(1):CD004754. PubMed
  16. Carlton, S., Clopton, D., and Cappuzzo, K. A. Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity. Consult Pharm 2010;25(3):171-177. PubMed
  17. Wang, H., Xia, N., Yang, Y., and Peng, D. Q. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2012;11:42. PubMed
  18. Turner AN, Carr Reese P, Fields KS, Anderson J, Ervin M, Davis JA, Fichorova RN, Roberts MW, Klebanoff MA, Jackson RD. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet G PubMed
  19. Weiner M, Epstein FH. Signs and symptoms of electrolyte disorders. Yale J Biol Med. 1970;43(2):76-109.
  20. Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017 Mar 28;317(12):1234-1243. PubMed
  21. Roth DE, Leung M, Mesfin E, Qamar H, Watterworth J, Papp E. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. BMJ. 2017;359:j5237. PubMed
  22. Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial. JAMA. 2021.
  23. Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol 2013;136:54-8. PubMed
  24. Doyle D, Browne U, Brickley A, Murphy D. Vitamin D-induced hypercalcaemia and acute kidney injury in sarcoidosis. BMJ Case Rep 2023;16(1):e250580. PubMed
  25. Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database Syst Rev 2023;2(2):CD011511. PubMed
  26. Kinesya E, Santoso D, Gde Arya N, et al. Vitamin D as adjuvant therapy for diabetic foot ulcers: Systematic review and meta-analysis approach. Clin Nutr ESPEN 2023;54:137-143. PubMed

See these in context on the Vitamin D monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring
Supplement interaction checker › Check any supplement or product against your medications Drug–drug interactions › Check two or more of your medications against each other Browse medications A–Z › Every drug we've checked against herbs & supplements NDC & pricing lookup › Find a drug’s NDCs, packaging and costs Ask a pharmacist › Free, personal answer from our licensed team